All In MedTech

Device Trial Radar · NCT02993276

Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

Protect Neuro - Prospective Cohort Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

Last checked: Nov 20, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Apr 17, 2017

Primary completion

Jul 6, 2018

Study completion Aug 30, 2020

Sponsor

Lead sponsor
Polyganics BVNot on our public-company list
Sponsor type
Industry
First posted
Dec 15, 2016

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro) This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.

Conditions

  • Neuroma

Interventions

  • Neurocap®Device

    NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analog Scale (VAS) for PainTime frame: 2 years

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Arizona Center for Hand Surgery

    Phoenix, Arizona

  • Stanford Medical Center Hand and Upper Limb Center

    Redwood City, California

  • Buncke Clinic

    San Francisco, California

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.